Story

BioMérieux Most Exposed to China's New Lab-Fee Reforms, Morgan Stanley Says

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20262 min read
BioMérieux Most Exposed to China's New Lab-Fee Reforms, Morgan Stanley Says
Text size
Background

Morgan Stanley has analyzed the potential financial impact of China's new laboratory-fee reforms on major European diagnostics companies, identifying bioMérieux as the most exposed to the pricing pressure. The investment bank's report follows an August 14 announcement from China's National Healthcare Security Administration (NHSA) detailing a new policy covering more than 600 test reagents and analytes.

China's Pricing Overhaul

The reform introduces significant pricing changes for lab tests. In its base case scenario, Morgan Stanley assumes a 15% net price compression for the affected products. Analysts at the bank noted this is below the headline 20%-40% multiplex-discount range, as they expect the impact to be partially offset by increased testing volumes and the use of premium add-on services.

Company-Specific Exposure

Morgan Stanley estimated the potential impact on each company's fiscal year 2027 earnings before interest and taxes (EBIT), assuming a 100% drop-through from the price cuts. The analysis ranks the companies' exposure as follows:

  • bioMérieux: The French firm faces the highest risk, with a potential 5% hit to FY27 EBIT. China represents about 5% of its group sales.
  • DiaSorin: The Italian company is ranked second, with an estimated 2% EBIT impact. China accounts for approximately 3% of its sales.
  • Siemens Healthineers & Qiagen: Both companies are estimated to have the lowest exposure, with a potential 1% impact on group EBIT each.
Sample IUX Markets – In-articleAd

Business Line Risks and Mitigating Factors

For bioMérieux, the exposure is concentrated in its Microbiology and Immunoassay segments, specifically its BACT/ALERT and VITEK platforms. While its dominant market share in China could limit customers from switching to rivals, the bank noted the company has already experienced weaker dynamics in the region.

DiaSorin has already guided for a €5 million impact from China's separate volume-based procurement (VBP) initiative in 2026 and previously closed its Shanghai manufacturing site. In contrast, Qiagen is seen as potentially better insulated due to its wide range of premium molecular add-ons, which could cushion the pricing impact on its molecular tests.

Despite having the highest share of Diagnostics sales from China among the four companies at 7%, Siemens Healthineers' group-level EBIT impact is estimated at just 1%. However, Morgan Stanley cautioned that this segment-level sensitivity could be understated due to the division's already-low margins and a planned corporate carve-out of the diagnostics business.

Read next

More on Stocks
Back to latest news

LATEST